0001213900-25-045399.txt : 20250519 0001213900-25-045399.hdr.sgml : 20250519 20250519161010 ACCESSION NUMBER: 0001213900-25-045399 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250514 FILED AS OF DATE: 20250519 DATE AS OF CHANGE: 20250519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levy Richard S CENTRAL INDEX KEY: 0001454983 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36694 FILM NUMBER: 25963993 MAIL ADDRESS: STREET 1: 860 WASHINGTON STREET STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protara Therapeutics, Inc. CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 204580525 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-844-0337 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: ArTara Therapeutics, Inc. DATE OF NAME CHANGE: 20200110 FORMER COMPANY: FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC DATE OF NAME CHANGE: 20060420 4/A 1 marketforms-69540.xml PRIMARY DOCUMENT X0508 4/A 2025-05-14 2025-05-16 0001359931 Protara Therapeutics, Inc. TARA 0001454983 Levy Richard S C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 3RD FLOOR NEW YORK NY 10010 true false false false 0 Common Stock 2025-05-14 4 P false 20000 3.19 A 51000 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.15 to $3.22, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. This amendment is to revise the footnote above to reflect that the transactions that are the subject of this Form 4 were purchases, not sales, of shares of TARA. /s/ Mary Grendell, Attorney-in-fact 2025-05-19